Kalaris Therapeutics Q3 net loss narrows as expenses fall
KLRS•Kalaris Therapeutics reported a third-quarter net loss of $11.03 million as operating expenses fell to $11.81 million. A supply interruption delayed preliminary TH103 Phase 1b/2 data to the second half of 2027; the company expects cash to fund operations into 2028.
1. Quarterly results and outlook
Kalaris Therapeutics’ third-quarter net loss narrowed from a year earlier as operating expenses declined to $11.81 million, with a net loss of $11.03 million. A supply interruption pushed preliminary TH103 Phase 1b/2 data in nAMD to the second half of 2027; the company expects to start a Phase 3 program in 2028 and says its cash resources should fund operations into 2028.
